Tag: Bharat Biotech

An entirely new “chimeric” spike antigen complex, different from any protein of existing SARS-CoV-2 variants, will be generated

Covaxin has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study in children 2-18 years of age

Despite receiving emergency use listing from the World Health Organization, Covaxin has not been cleared for any age group in the United States

Normally a vaccine development process takes 6-8 years for research and trials, but path-breaking work has been done in India

The trials for 0.5 ml single dose of nasal vaccine will be conducted at nine locations in the country.

Dr Cyrus Poonawalla of Serum Institute of India; and Dr Krishna Ella and Suchitra Ella of Bharat Biotech have found their place in the just released list of Padma Awards. They will be honored with Padma Bhushan for the role played by their companies during Covid-19 pandemic

Dr. Krishna Ella, Chairman & Managing Director of Bharat Biotech International Limited delivered this year’s Foundation Day Lecture virtually on ‘Innovation and Leadership in Pandemic’

100% of test serum samples showed neutralization of the Delta variant and more than 90% of serum samples showed neutralization of the Omicron variant

The phase 2, double-blind, randomised controlled COVAXIN trial demonstrated long-term safety with no serious adverse events

As a precautionary measure, the healthcare workers and doctors will be given additional Covid-19 vaccine doses from January 10, 2022. Also, the people with co-morbidities and 60 years of age will get booster doses